Citius Oncology Inc. (CTOR)
NASDAQ: CTORHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CTOR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $53.25M
- EPS (TTM)
- -$0.48
- Dividend yield
- None
- 52-week range
- 0.491 – 1.83
- Day range
- 0.502 – 0.5698
- Volume / Avg
- 52.63K / 114.02K
- Beta
- —
- Shares outstanding
- 105.76M
- Next earnings
- Dec 22, 2026
52-week range
CTOR stock today
Citius Oncology (CTOR) closed at $0.5035 on Nov 20, down 10.95% (-$0.0619), versus the S&P 500's 3.70% decline. Trading was light, with 52.63K shares changing hands, about 46% of the average daily volume. At this level, CTOR sits near the bottom of its 52-week range of $0.491 to $1.83: 72.5% below the high, set on Dec 1, 2025 and 2.5% above the low.
CTOR is down 49.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 55.4%. Citius Oncology has posted a net loss over the last twelve months (EPS of -$0.48), so its P/E ratio is not meaningful. Citius Oncology's next earnings report is expected on Dec 22, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Citius Oncology
Company profileCitius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Leonard L. Mazur
- Headquarters
- Cranford, NJ
- IPO year
- 2022
Financial highlights
Full financialsCitius Oncology reported a net loss of $24.8 million, compared with a loss of $21.1 million a year earlier. Diluted earnings per share came in at -$0.34.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-24.76M | $-21.15M | $2.42M | $-12.70M | $380.81K |
| EPS (diluted) | $-0.34 | $-0.31 | $0.27 | $-0.19 | $0.12 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$4.00+694.44%
- Strong buy 1
- Buy 0
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Dec 22, 2026
- Last reported (Q3 2026)
- Aug 14, 2026
- EPS actual vs est.
- $-0.08 vs —
CTOR news
All CTOR newsCitius Oncology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LFVNLifevantage Corporation | 4.15 | -15.13% | $52.63M | vs CTOR |
| XBITXBiotech Inc. | 1.73 | +2.98% | $52.74M | vs CTOR |
| XLOXilio Therapeutics Inc. | 7.56 | -1.11% | $53.40M | vs CTOR |
| ALDXAldeyra Therapeutics Inc. | 0.84 | +16.39% | $50.70M | vs CTOR |
| CLNNClene Inc. | 3.52 | +0.57% | $50.69M | vs CTOR |
| BOLDBoundless Bio Inc. | 2.32 | -2.52% | $54.78M | vs CTOR |
| AZRAzora Therapeutics Inc. | 3.85 | -0.52% | $55.00M | vs CTOR |
| ACRVAcrivon Therapeutics Inc. | 1.15 | -17.86% | $49.35M | vs CTOR |
Indexes, lists and sector
Citius Oncology stock FAQ
What is Citius Oncology's stock price today?
CTOR last traded at $0.5035 as of Nov 20, 4:00 PM EST, down 10.95% on the day. Prices are delayed at least 15 minutes.
When is Citius Oncology's next earnings date?
Citius Oncology is expected to report earnings on Tuesday, December 22, 2026.
Who is Citius Oncology's CEO?
Mr. Leonard L. Mazur is the chief executive officer of Citius Oncology Inc..
What is the CTOR 52-week high?
The 52-week high for CTOR is $1.83 and the 52-week low is $0.491. The stock is currently 72.5% below its high.